PDGF-B analogues

• US 5,512,545 A
• Filed: 08/31/1993
• Issued: 04/30/1996
• Est. Priority Date: 01/25/1991
• Status: Expired due to Fees

• Current Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: British Biotech Pharmaceuticals Limited, Pfizer Limited (Pfizer Inc.)
• Inventors: Brown, David, Edwards, Richard M., Clements, John M., Cook, Anne L., Craig, Stewart
• Primary Examiner(s): Allen, Marianne P.
• Application Number:
  US08/094,079
• Time in Patent Office: 973 Days
• Field of Search: 435/69.1, 435/69.4, 435/172.3, 435/320.1, 435/240.2, 435/252.33, 435/255.1, 435/255.2, 530/350.399, 514/2, 514/8, 514/12, 536/23.5, 536/23.51
• US Class Current: 514/8.2
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/49 Platelet-derived growth factor [PDGF]

Abstract

PDGF-B analogues are prepared in which an amino acid residue at a protease site is replaced with the corresponding amino acid residue from PDGF-A. The polypeptide is obtained at yields which are five to ten times greater than that for naturally occurring PDGF-B and retains the biological activity of the natural polypeptide.

Claims